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Abstract
Human serum albumin (HSA) nanoparticles represent a promising tool for targeted drug delivery to tumor cells.
The coupling of the antibody trastuzumab to nanoparticles uses the capability of human epidermal growth factor
receptor 2 (HER2)–positive cells to incorporate agents linked to HER2. In our present study, we developed targeted
nanoparticles loaded with antisense oligonucleotides (ASOs) against polo-like kinase 1 (Plk1). We evaluated the
receptor-mediated uptake into HER2-positive and -negative breast cancer and murine cell lines. We performed
quantitative real-time PCR and Western blot analyses to monitor the impact on Plk1 expression in HER2-positive
breast cancer cells. Antibody-conjugated nanoparticles showed a specific targeting to HER2–overexpressing cells
with cellular uptake by receptor-mediated endocytosis and a release into HER2-positive BT-474 cells. We observed
a significant reduction of Plk1 mRNA and protein expression and increased activation of Caspase 3/7. Thus, this is
the first report about ASO-loaded HSA nanoparticles, where an impact on gene expression could be observed. The
data provide the basis for the further development of carrier systems for Plk1-specific ASOs to reduce off-target
effects evoked by systemically administered ASOs and to achieve a better penetration into primary and metastatic
target cells. Treatment of tumors using trastuzumab-conjugated ASO-loaded HSA nanoparticles could be a prom-
ising approach to reach this goal.
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Introduction
Antibodies are well-established tools to target drugs or colloidal
carriers to specific cell types [1–3]. This targeted delivery reduces
possible side effects and off-target effects. In addition, increasing
knowledge about the genetic control of cellular proliferation provides
the basis for specific therapeutic strategies to combat proliferative
disorders such as cancer. Key regulators for mitosis in mammalian
cells are the polo-like kinases (Plks), which represent highly con-
served serine/threonine kinases [4]. Polo-like kinase 1 (Plk1) activity
is elevated in all cancer cells analyzed to date [5]. The importance
of Plk1 for the aggressiveness of a tumor and for predicting outcomes
in cancer patients results from its contribution to transformation
and from overriding the checkpoint control of the cell cycle [6–8].
The inhibition of Plk1 with antibodies, antisense oligonucleotides
(ASOs), small interfering RNA (siRNA), or dominant-negative mu-
tants leads to mitotic catastrophe, increased apoptosis, and tumor in-
hibition [9–15]. Antisense oligonucleotides can, when targeted to
key elements of proliferation-relevant signal transduction pathways,
prevent the development of specific human cancers. Several phos-
phorothioate ASOs are currently being evaluated in patients suffering
from different types of cancer [16], suggesting ASOs as valuable
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agents for therapeutic approaches. Although the power of ASOs
remains unrivaled, the dose-limiting side effects and toxicities of phos-
phorothioate ASOs in their relevant doses [16,17] or inadequate
penetration into the target tumor tissue emphasize the necessity of
further improvements in ASO chemistry and delivery systems [18],
especially of targeted delivery through specific cell surface recep-
tors [19–21].
Trastuzumab (Herceptin) is a humanized IgG1 monoclonal anti-
body directed against the extracellular domain of the human epider-
mal growth factor receptor 2 (HER2), which offers an excellent
strategy for drug targeting to cancer cells because HER2 is an easily
accessible cell surface receptor overexpressed on the primary tumor as
well as on metastatic sites [22]. Biodegradable human serum albumin
(HSA)–based nanoparticles represent a nontoxic colloidal carrier sys-
tem with high drug loading capacity [23], which have been extensively
studied in clinical settings with the cremophor-free formulation of pac-
litaxel (Abraxane, ABI-007) [24,25]. Drugs can be incorporated within
the particle matrix, adsorbed on the particle surface, or bound by co-
valent linkage [26,27]. By this, the drug is protected against degrada-
tion, and controlled release is enabled [28].
The aim of the present study was to develop ASO-loaded HSA
nanoparticles as cell type–specific drug delivery system with receptor-
mediated uptake, release into the cytoplasm, and a functional read-
out concerning Plk1 expression. We observed for the first time a
receptor-mediated cellular uptake of ASO-loaded trastuzumab-
modified HSA nanoparticles with an inhibitory effect on Plk1 expres-
sion. Hence, this drug delivery system could provide the basis for a
targeted therapy of HER2-positive cancers with Plk1-specific ASOs.
Materials and Methods
Reagents and Chemicals
Human serum albumin (fraction V) and glutaraldehyde, 8% aque-
ous solution, were obtained from Sigma (Steinheim, Germany).
2-Iminothiolane (Traut’s reagent), and D-Salt Dextran Desalting col-
umns were purchased from Pierce (Rockford, IL). The succinimidyl
ester of methoxy poly(ethylene glycol)propionic acid with an average
molecular weight of 5.0 kDa (mPEG5000-SPA) and the cross-linker
poly(ethylene glycol)-α-maleimide-ϖ-NHS ester with an average
molecular weight of 5.0 kDa (NHS-PEG5000-Mal) were purchased
from Nektar Therapeutics (Huntsville, AL). Monoclonal anti–
human Plk1 (#SC-17783), polyclonal rabbit Plk2 (#SC-25421)
polyclonal goat Plk4 antibody (#SC-49101), polyclonal rabbit p38
antibody (#SC-535), and goat anti–mouse (#SC-2031), goat anti–
rabbit (#SC-2030), and donkey anti–goat (#SC-2033) secondary
antibodies were from Santa Cruz Biotechnology, Inc. (Heidelberg,
Germany); monoclonal antibody against HER2 (#OP15L) was from
Oncogene Research Products (Calbiochem, Nottingham, UK); and
monoclonal antibody against β-actin (#A-5316) was from Sigma-
Aldrich (Taufkirchen, Germany). Trastuzumab (Herceptin) was ob-
tained from Roche (Mannheim, Germany). All reagents were of
analytical grade and were used as received.
The phosphorothioate antisense oligonucleotides were P12 (tar-
geted against Plk1: acc agt ccg gag ggg agg gc) and HSV (targeted
against the Herpes Simplex Virus: gcg gag gtc cat gtc gta cgc) as de-
scribed before [10,29]. For cellular distribution studies a Cy5-labeled
phosphorothioate oligonucleotide (cta cga tct act ggc tcc at) was pur-
chased from MWG-Biotech GmbH (Ebersberg, Germany).
Cell Culture
The breast cancer cell lines MCF-7 and BT-474 and the murine fi-
broblast cells NIH-3T3 and murine myoblast cells C2C12 were ob-
tained from DSMZ (Braunschweig, Germany), and SK-BR-3 cells
were from ATCC (LGC Promochem, Wesel, Germany). All cell lines
were cultured according to the supplier’s instructions without antibio-
tics. Fetal calf serum was purchased from PAA Laboratories (Cölbe, Ger-
many). McCoy’s medium was from BioWhittaker (Apen, Germany),
RPMI 1640, sodium pyruvate, phosphate-buffered saline (PBS), gluta-
mine, and trypsin were from Invitrogen (Karlsruhe, Germany), and bo-
vine insulin was from Calbiochem (Schwalbach, Germany).
Preparation of ASO-Loaded HSA Nanoparticles
Human serum albumin (20.0 mg) was dissolved in 500 μl of pu-
rified water, and the pH was adjusted to 5.5. An amount of 300.0 μg
of the respective ASO (P12 and HSV) was added, and the mixture
was stirred for 15 minutes. To form nanoparticles, 2.7 ml of 96%
ethanol was added at a rate of 1 ml/min with a tubing pump
(IPN; Ismatec, Glattbrugg, Switzerland) under constant stirring
(550 rpm) at room temperature as established in earlier publications
[30,31]. Particles were stabilized by cross-linking with 0.03% glutar-
aldehyde solution (11.8 μl from the 8% stock solution) for at least
12 hours under constant stirring at room temperature. Particles were
purified by centrifugation (16,100g for 8 minutes) and redispersion
of the pellet in phosphate buffer, pH 8.0.
The coupling reaction of trastuzumab with the ASO-loaded nano-
particles was performed as described [31]. Nanoparticles (10 mg)
were activated with NHS-PEG5000-Mal (8.8 mg). Trastuzumab
was thiolated with 50-fold molar excess of 2-iminothiolane. For cou-
pling reactions, the nanoparticle suspension was incubated with thio-
lated trastuzumab for at least 12 hours. Samples were purified as
described earlier. Particles with PEG-modified surface instead of tras-
tuzumab coupling were prepared as described previously [31].
Unloaded particles were prepared as described [31] at a pH of 7.5.
Modifications were performed according to the ASO-loaded particles.
Particle Characterization
The amount of ASO bound to the nanoparticles was calculated as
the difference between the total amount of the initial ASO added
and the amount of ASO determined in the supernatants obtained
during the purification steps. The ASO content was determined by
a strong ion-exchange HPLC assay as described [30], using a 4×
250-mm column (DNApac PA100; Dionex, Idstein, Germany) and
an HPLC system (Hitachi; Merck, Darmstadt, Germany). The
amount of trastuzumab bound to the particle surface was analyzed
by size exclusion chromatography as described previously [31].
Particle diameter and polydispersity were measured by photon cor-
relation spectroscopy, and zeta potential was determined by micro-
electrophoresis using Zetasizer 3000 HSa (Malvern Instruments,
Malvern, UK). Before measurement, the samples were diluted with
purified water. Particle content was determined by gravimetry.
Storage Stability
Trastuzumab-modified particles loaded with P12 were prepared
and analyzed as described earlier. Without any additional agents,
the particle samples were stored in purified water at 4°C for a period
of 6 weeks. Once a week, particle diameter, polydispersity, and zeta
potential were measured. Additionally, an aliquot of the particle
suspension was centrifuged, and the supernatant was analyzed for
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trastuzumab, HSA, and P12 using the chromatographic methods de-
scribed earlier.
Treatment of Breast Cancer Cells with ASO-Loaded
Trastuzumab-Modified Nanoparticles
To investigate the cell-specific binding, uptake and release efficiency
of trastuzumab-modified compared to PEGylated HSA nanoparticles
and to analyze the inhibitory effect of the incorporated ASOs on
Plk1 expression, cells were seeded in 12-well plates, 75-cm2 cell cul-
ture flasks or on slide flasks, respectively, and were grown to 40%
to 50% confluence. Cells were treated with trastuzumab-modified
and with PEGylated nanoparticles in a concentration of 100 μg/ml
in cell culture medium at 37°C and 5% CO2 as described [30].
Additionally, to confirm the specificity of particle binding to HER2-
overexpressing cells, in the case of SK-BR-3 and BT-474 cells, experi-
ments were performed with and without preincubating with 2.5 μg/ml
trastuzumab for 30 minutes at 37°C.
After nanoparticle incubation for 30 minutes, 60 minutes, 3 hours,
5 hours, and 24 hours cells were harvested for fluorescence-activated cell
sorting (FACScan) analysis, after 48 hours for reverse transcription–
polymerase chain reaction (RT-PCR), after 24 and 48 hours for quan-
titative real-time PCR, after 24, 48, and 72 hours for Western blot
analysis, and after 72 hours for apoptosis analyses. For the RT-PCR,
quantitative real-time PCR, Western blot, and apoptosis analyses,
nanoparticle suspensions were removed from the cells after an incu-
bation time of 60 minutes, and fresh medium was added.
FACScan Analysis of ASO-Loaded HSA Nanoparticles
FACScan analysis to detect the autofluorescence of the particles
within the cells was performed using a Becton Dickinson FACScan
apparatus (Heidelberg, Germany) as described [31]. In brief, cells
were harvested, washed with PBS, resuspended in cold PBS (pH
7.4), and ethanol was added. After 30 minutes of incubation on
ice, cells were centrifuged and resuspended in PBS. For each exper-
iment, 10,000 cells were analyzed in triplicate. Subsequent analysis
was performed with CELLQuest software (Becton Dickinson).
Confocal Laser Scanning Microscopy Analysis of Nanoparticle
Uptake in BT-474 Cells
For the analysis of the cellular uptake by confocal laser scanning
microscopy, the nanoparticles were prepared with Cy5-labeled ASO in-
stead of P12. After incubating with trastuzumab-modified or PEGylated
nanoparticles, cells were washed with PBS for 15 minutes. Membrane
staining was carried out using Alexa594 Concanavalin A (Molecular
Probes, Göttingen, Germany; 500 μl, 0.0005%) for 2 minutes. Cells
were washed with PBS, fixed with −20°C cold methanol for 15 minutes,
and washed with PBS. Then the slides were embedded with Vectashield
(Vector, Burlingame, CA).
RNA Preparation and RT-PCR Analysis of Plk1 and
GAPDH Expression
Total RNA from cultured cells was isolated using RNeasy Mini Kits
according to the manufacturer’s protocol 48 hours after incubating
with the nanoparticle formulations (Qiagen, Hilden, Germany). For
RT-PCR, the QIAGEN OneStep RT-PCR Kit was used according
to the supplier’s instructions (Qiagen). Two micrograms of total
RNA were added to the PCR mix containing Plk1-specific or
GAPDH-specific primers, respectively, and the RT reactions were car-
ried out as described [29]. Resulting DNA fragments were separated
on 1% agarose gels and visualized by ethidium bromide staining.
Quantitative Real-Time PCR Analysis
After isolation of total RNA using RNeasy Mini Kits (Qiagen)
according to the manufacturer’s protocol 24 and 48 hours after
incubating with the nanoparticle formulations, the mRNA was
transcribed into cDNA using the High-Capacity cDNA Reverse
Transcription Kits (Applied Biosystems, Darmstadt, Germany).
Thereafter, 50 ng of cDNA was subjected to quantitative real-time
PCR analyses targeting Plk1 and GAPDH using the FastStart Uni-
versal Probe Master ROX and Universal ProbeLibrary #30 (Plk1) and
#60 (GAPDH) (Roche). Primer sequences were chosen as suggested
by Roche: Plk1 forward 5′-cacagtgtcaatgcctccaa, Plk1 reverse 5′-
ttgctgacccagaagatgg, GAPDH forward 5′-agccacatcgctcagacac,
GAPDH reverse 5′-gcccaatacgaccaaatcc. Analysis was performed
using the StepOne Real-Time PCR System and the StepOne v2.0
software (Applied Biosystems). Relative gene expression values were
determined by the ΔΔCT method using the StepOne v2.0 software
(Applied Biosystems). Data are presented as the fold difference in
Plk1 expression normalized to the housekeeping gene GAPDH as
endogenous reference, and relative to the untreated control cells.
Western Blot Analysis
For Western blot analysis, breast cancer and murine cells were
lysed after 24, 48, and 72 hours after incubating with the nanopar-
ticle formulations, and protein concentration was determined as pre-
viously described [9,29]. An amount of 50 μg of total protein was
separated on 10% Bis-Tris-polyacrylamide gels and then transferred
(30 V, 1 hour) to Immobilon-P membranes (Millipore, Bedford,
MA) according to the Invitrogen protocol. Membranes were incu-
bated for 1 hour in 5% powdered nonfat milk in PBS with mono-
clonal antibodies against HER2 (1:250), Plk1 (1:100), Plk2 (1:200),
Plk4 (1:200), p38 (1:20,000), and β-actin (1:200,000) and for
30 minutes in 5% nonfat dry milk with goat anti–mouse, goat anti–
rabbit, or donkey anti–goat serum, respectively (1:2000), and visual-
ized as described [9].
In Western blot and RT-PCR experiments, Plk1 expression levels
were routinely normalized to levels of GAPDH, p38, or β-actin
expression, respectively. The resulting GAPDH-, p38-, or β-actin–
normalized Plk1, Plk2, or Plk4 levels, respectively, are presented rel-
ative to GAPDH-, p38-, or β-actin–normalized levels in untreated
cells. Polo-like kinase 1, Plk2, Plk4, HER2, GAPDH, p38, and β-
actin expressions were quantified with a gel documentation system
(Model 1D 3.5; Kodak, Stuttgart, Germany) as described previously [9].
Apoptosis Assay
We performed Caspase-Glo assays to detect activation of Caspase
3/7 using the Caspase-Glo 3/7 Assay System (Promega, Mannheim,
Germany). In brief, cells were analyzed 72 hours after incubating
with the nanoparticle formulations. We used an amount of 10 or
20 μg of total protein, respectively, to detect the activation of Cas-
pase 3/7. Cell lysates were mixed with the Caspase-Glo substrate, in-
cubated for approximately 30 minutes, and thereafter analyzed using
a multilabel counter (Victor 1420; Perkin Elmer Wallac, Freiburg,
Germany). These assay systems provide substrates that are processed
by activated caspases to aminoluciferin which, itself, is a substrate
for luciferase. The emitted light can be measured at 562 nm referred
to as relative luminescence units (RLUs). RLU levels of nanoparticle-
treated cells were presented relative to RLU levels of untreated con-
trol cells.
Neoplasia Vol. 10, No. 3, 2008 Plk1 Downregulation by ASO-Loaded Nanoparticles Spänkuch 225
Statistical Methods
Two-way analysis of variance (GraphPad Prism; GraphPad Soft-
ware, Inc., San Diego, CA) was performed as described [9].
Results
HER2 Expression of Breast Cancer and Murine Cell Lines
In a first set of cell culture experiments, we analyzed the expression
of endogenous HER2 protein levels in different breast cancer and
murine cells by Western blot analysis. We included two murine cell
lines in our studies to evaluate a potential nanoparticle uptake in mu-
rine cells for future cancer xenograft experiments.
Membranes were incubated with antibodies against HER2 and
β-actin. While in the case of MCF-7, NIH-3T3 and C2C12 cells,
the level of HER2 was below the limit of detection, strong ex-
pression was observed in BT-474 and especially in SK-BR-3 cells,
which is in agreement with previous observations [31,32] (Figure 1).
This confirms suitable conditions for the analysis of trastuzumab-
conjugated nanoparticles.
Preparation and Characterization of ASO-Loaded
HSA Nanoparticles
HSA nanoparticles loaded with ASO were prepared using a desol-
vation technique. Before desolvation, the HSA solution was incubated
with ASOs allowing the ASO to adsorb to the HSA molecules. During
desolvation, the ASO precipitates with the HSA molecules, forming
nanoparticles. After stabilization and purification, the particle surface
was modified with the cross-linker NHS-PEG5000-Mal. The succini-
midyl group reacts with the amino groups of the particle surface, and
the maleimide group reacts with the thiol groups introduced in tras-
tuzumab, forming a thioether linkage (Figure 2). The PEG modifica-
tion prevents unspecific binding of plasma components to the particle
surface and uptake in cells of the reticuloendothelial system [33].
The coupling of trastuzumab enables a site-specific targeting of the
nanoparticles to HER2-overexpressing cancer cells. As control, nano-
particles without antibody coupling were prepared using a monofunc-
tional PEG derivative.
The ASO-loaded nanoparticles were 267 to 278 nm in diameter,
and particles without ASO loading were 192 to 196 nm in diameter
(Table 1). All preparations showed a monodisperse diameter distri-
bution, the surface charge was between −30 and −40 mV. The par-
ticles contained approximately 20 μg/mg ASO. No differences in
loading could be observed between P12 and HSV. Trastuzumab
was attached quantitatively to the nanoparticle surface, leading to
17 μg of trastuzumab/mg nanoparticle.
Storage Stability
For stability investigations, the physico-chemical properties of the
P12-loaded trastuzumab-modified particles were monitored for a pe-
riod of 6 weeks. Particle diameter, polydispersity, and zeta potential
did not change significantly (Table 2). Furthermore, the particle sus-
pensions were centrifuged, and the supernatants were analyzed for
unbound trastuzumab and dissolved HSA by size exclusion chroma-
tography. Over time, neither trastuzumab nor HSA was detectable.
The analyses of the supernatants by ion exchange chromatography
revealed a drug leakage of P12 of up to 6% of the total drug loading.
Therefore, the particle system was stable over the observed time span
and can be stored after preparation.
Specific Cellular Uptake of
Trastuzumab-Modified Nanoparticles
To analyze whether the conjugation of trastuzumab is an effective
method for specific targeting of HER2-positive breast cancer cells, we
investigated the time-dependent uptake of trastuzumab-modified
versus PEGylated ASO-loaded nanoparticles in HER2-positive SK-
BR-3 and BT-474 cells and HER2-negative MCF-7 cells (Figure 3)
by FACScan analysis. The uptake of unloaded HSA nanoparticles
has been intensively examined in a previous study [31].
In a first experiment, we analyzed the uptake in BT-474 cells
(Figure 3, left panels). After 60 minutes of incubation, we observed
a significant enrichment of trastuzumab-modified nanoparticles loaded
with P12 in 60.09% of BT-474 cells compared to 1.91% in the case of
Figure 1. Expression of HER2 in breast cancer and murine cell
lines. A Western blot analysis was performed using anti–HER2
antibodies. To control for variability of loading, membranes were
reprobed with antibodies against β-actin. The expression of HER2
in BT-474, C2C12, MCF-7, NIH-3T3, and SK-BR-3 cells is depicted
in alphabetical order.
Figure 2. Schematic representation of the antibody surface modification of the ASO-loaded nanoparticles. Trastuzumab was covalently
attached to the particle surface by a PEG-based heterobifunctional cross-linker.
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P12-loaded PEGylated nanoparticles. For trastuzumab-modified
HSV-loaded nanoparticles, the uptake was 65.23% compared to
5.30% for PEGylated nanoparticles. In SK-BR-3 cells, the uptake
followed a similar kinetics (Figure 3, middle panels): P12-loaded
trastuzumab-modified HSA nanoparticles showed receptor-mediated
uptake with enrichment of 65.36% compared to 3.17% for PEGylated
P12-loaded nanoparticles after 60 minutes of incubation. HSV-loaded
trastuzumab-modified nanoparticles showed enrichment in 60.69%
of SK-BR-3 cells compared to 4.45% for PEGylated nanoparticles.
For both HER2-positive cell lines, fluorescence after 60 minutes of
incubating with PEGylated nanoparticles was comparable to un-
treated control cells, indicating almost no affinity of the PEGylated
nanoparticles to breast cancer cells. HER2-independent uptake or up-
take mediated by recycled HER2 receptors of P12- and HSV-loaded
nanoparticles increased over the time of 24 hours (Figure 4, A and
B). Only the P12-loaded PEGylated nanoparticles showed slight
HER2-independent uptake over the period of 24 hours.
HER2-negative MCF-7 cells showed no significant differences in
the uptake of trastuzumab-modified and PEGylated nanoparticles
after 30 minutes to 24 hours of incubation (Figures 3, right panels,
and 4C ). Uptake increased in a time-dependent, HER2-independent
manner for all nanoparticle formulations. For the P12- and HSV-
loaded nanoparticles, the difference between trastuzumab-modified
and PEGylated nanoparticles was even stronger than that for the un-
loaded particles, which might be due to the slightly smaller diameter
of the unloaded particles compared to ASO-loaded particles.
In addition, we analyzed the effect of a preincubation of HER2-
positive cells (BT-474 and SK-BR-3) with trastuzumab on the uptake
of ASO-loaded and -unloaded trastuzumab-conjugated nanoparti-
cles. Therefore, we incubated the cells with 2.5 μg/ml trastuzumab
for 30 minutes at 37°C before the addition of the nanoparticle for-
mulations. We observed that, after this preincubation, cell binding
sites could be effectively blocked, and after 30 and 60 minutes, no
significant difference in cellular accumulation between trastuzumab-
modified and PEGylated nanoparticles loaded with P12 or HSV, re-
spectively, was detectable (Figure 4, A and B). After incubation per-
iods of 3, 5, and 24 hours, HER2-independent uptake or uptake
mediated by recycled HER2 receptors increased up to levels compa-
rable with the specific antibody-mediated uptake of trastuzumab-
modified nanoparticles.
Cellular Uptake of Trastuzumab-Modified Nanoparticles
into Normal Murine Cells
Next we analyzed whether the trastuzumab-modified or PEGylated
unloaded or ASO-loaded HSA nanoparticles could be enriched in
murine cells. We used NIH-3T3 and C2C12 cells and incubated
these cell lines with the nanoparticle preparations as described earlier
for the breast cancer cells. We observed only a slight time-dependent,
HER2-independent uptake of the different nanoparticle prepara-
tions: in NIH-3T3 cells, uptake levels were below 20% after 30 min-
utes to 24 hours of incubation (data not shown), and in C2C12,
uptake levels were below 20% up to 5 hours of incubation and
showed a slight increase up to 40% after 24 hours of incubation (data
not shown).
Uptake and Release of ASO-Loaded
Trastuzumab-Modified Nanoparticles
We investigated the time course of the release of trastuzumab-
modified nanoparticles with a Cy5-labeled ASO in HER2-positive
BT-474 cells compared to PEGylated nanoparticles containing the
same ASO. For this purpose, we performed confocal laser scanning
microscopy studies, where we observed a time-dependent release
of the Cy5-labeled ASO over a period of 1 to 24 hours (Figure 5).
After 60 minutes, the released ASO could only be detected for the
trastuzumab-modified nanoparticles and not for the PEGylated nano-
particles, underlining the receptor-mediated uptake.
Downregulation of Plk1 mRNA and Protein Expression
To investigate whether the trastuzumab-modified ASO-loaded nano-
particles show a biologic activity, we performed RT-PCR, quantitative
real-time PCR, and Western blot analyses to determine the Plk1
mRNA and protein expression.
Table 1. Physico-chemical Characteristics of Trastuzumab-Modified and PEGylated HSA Nanoparticles Loaded With P12- or HSV-ASO or Unloaded (n = 15).
Preparation P12 + Trastuzumab P12 + mPEG HSV + Trastuzumab HSV + mPEG Unloaded + Trastuzumab Unloaded + mPEG
Particle diameter (nm) 277.9 ± 42.6 267.2 ± 39.6 273.5 ± 35.3 271.5 ± 34.8 196.0 ± 12.7 191.6 ± 12.2
Polydispersity 0.060 ± 0.038 0.026 ± 0.020 0.035 ± 0.014 0.030 ± 0.015 0.049 ± 0.059 0.028 ± 0.020
Zeta potential (mV) −36.5 ± 4.6 −38.4 ± 7.1 −37.7 ± 8.8 −39.8 ± 7.0 −35.5 ± 10.4 −35.9 ± 7.5
Particle content (mg/ml) 15.3 ± 2.6 14.0 ± 1.4 14.7 ± 1.8 14.2 ± 1.8 17.9 ± 2.8 17.2 ± 2.3
Antibody binding efficiency (%) 100 0 100 0 100 0
(μg/mg) 17.59 ± 3.87 0 17.92 ± 3.89 0 15.14 ± 3.74 0
ASO loading (μg/mg) 19.37 ± 2.89 20.63 ± 1.98 20.56 ± 2.35 21.21 ± 2.21 0 0
Values are presented as mean ± SD.
Table 2. Storage Stability of P12-Loaded Trastuzumab-Modified Nanoparticles.
Parameter Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Diameter (nm) 263.8 ± 0.3 260.7 ± 3.8 259.6 ± 4.3 258.6 ± 3.5 265.7 ± 1.4 263.7 ± 3.5 266.6 ± 3.8
Polydispersity 0.092 ± 0.091 0.030 ± 0.030 0.025 ± 0.020 0.027 ± 0.025 0.022 ± 0.012 0.020 ± 0.012 0.067 ± 0.071
Zeta potential (mV) −43.1 ± 5.2 −32.0 ± 2.9 −36.9 ± 5.9 −31.5 ± 7.6 −37.9 ± 6.5 −36.1 ± 0.4 −36.5 ± 2.7
Trastuzumab (%) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
HSA (%) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
P12 (%) 3.5 ± 1.0 2.5 ± 0.4 3.2 ± 1.2 4.6 ± 1.2 5.3 ± 1.1 5.6 ± 1.5 6.3 ± 1.5
Physico-chemical properties were measured every week. The particle suspension was centrifuged and trastuzumab. HSA and P12 were determined in the supernatants. The time point Week 0 describes
the loss during preparation (n = 3).
Values are presented as mean ± SD.
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First, we incubated HER2-positive BT-474 cells with trastuzumab-
modified and PEGylated nanoparticles loaded with P12 and HSV and
with unloaded nanoparticles. Using RT-PCR, we observed a reduction
of Plk1 mRNA 48 hours after incubating with P12-loaded trastuzumab-
modified nanoparticles to levels of 77% (P < .05; Figure 6A) compared
to control cells. Incubation with all other nanoparticle formulations did
not alter Plk1 mRNA levels significantly.
To investigate this effect in more detail, we did quantitative real-time
PCR analyses 24 and 48 hours after incubating with the nanoparticle
formulations. The analysis of Plk1 gene expression standardized to
GAPDH expression revealed a nonsignificant reduction of Plk1 mRNA
expression 24 hours after incubating with P12-loaded trastuzumab-
modified nanoparticles compared to controls (P = .15; Figure 6B).
When we compared Plk1 mRNA expression 48 hours after incubating
Figure 3. Uptake of trastuzumab-modified and PEGylated nanoparticles with and without ASOs into HER2-positive and -negative breast
cancer cell lines. FACScan analysis of BT-474 (left panels), SK-BR-3 (middle panels), and MCF-7 cells (right panels) after 60 minutes of
incubating with the nanoparticles. M1 defines the cells without fluorescence (control), and M2 defines cells that show green fluores-
cence, indicating the uptake of nanoparticles.
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Figure 4. Uptake of trastuzumab-modified and PEGylated nanoparticles with and without ASOs into HER2-positive and -negative breast
cancer cell lines. Graphical summary of time-dependent uptake of trastuzumab-modified and PEGylated nanoparticles with and without
ASOs into (A) BT-474, (B) SK-BR-3, and (C) MCF-7 cells (n = 3, mean ± SD).
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with P12-loaded trastuzumab-modified nanoparticles with Plk1
mRNA expression in untreated control cells, the reduction was statis-
tically significant (P < .01; Figure 6C ).
To analyze whether this reduction in Plk1 mRNA was accompanied
by a reduction of Plk1 protein, we performed Western blot analyses in
BT-474 cells 24, 48, and 72 hours after incubating with the various
nanoparticle formulations. Therefore, we were able to additionally in-
vestigate the time dependency of the Plk1 protein reduction. We did
not observe a reduction of Plk1 protein after 24 or 48 hours, respec-
tively. Polo-like kinase 1 levels were comparable for all nanoparticle
formulations (Figure 6D, 24 hours; Figure 6E, 48 hours; P > .05 for
all formulations compared to untreated control cells). After 72 hours,
we observed a significant reduction of Plk1 protein expression after in-
cubating with P12-loaded trastuzumab-modified nanoparticles to levels
of 38% compared to control cells (P < .05; Figure 6F ). Polo-like ki-
nase 1 protein levels were not reduced significantly after incubating
with PEGylated P12-loaded nanoparticles, with HSV-loaded, and with
unloaded nanoparticles compared to controls (P > .05 for all treatments
compared to controls).
Treatment of BT-474 Cells with Plk1-Specific ASO-Loaded
Nanoparticles Does Not Influence Plk2 and Plk4
Protein Expression
To analyze whether incubation of BT-474 cells with P12-loaded
trastuzumab-modified nanoparticles does not only influence Plk1 ex-
pression but also the expression of other members of the Plk family,
we did Western blot analyses targeting Plk2 and Plk4, respectively,
72 hours after incubating with the nanoparticle formulations. We
did not observe significant changes in Plk2 and Plk4 protein expres-
sion standardized to p38 expression after incubating BT-474 cells
with P12-loaded trastuzumab-modified nanoparticles compared to
untreated control cells and compared to the other nanoparticle for-
mulations (Figure 7, A and B; P > .05 for all nanoparticle formula-
tions compared to untreated control cells).
Induction of Apoptosis
Because Plk1 inhibition has been shown to be associated with
apoptosis induction in earlier studies [9,12,29,34], we performed
apoptosis assays to evaluate the potential activation of Caspase 3/7 in
BT-474 cells after incubating with P12-loaded trastuzumab-modified
nanoparticles compared to control cells, to P12-loaded PEGylated
nanoparticles, and to HSV-loaded nanoparticles. Caspase 3/7 was in-
duced to levels of 165% (P < .01) using 10 μg of total protein after
treating with trastuzumab-modified nanoparticles and to 136% (P <
.05) with PEGylated nanoparticles compared to untreated controls
(Figure 7C ). The control ASO targeting HSV did not significantly in-
duce Caspase 3/7 compared to control cells (trastuzumab-modified:
115%, P = .21; PEGylated: 115%, P = .22). Using 20 μg of total
protein, Caspase 3/7 was induced to levels of 151% (P < .01) with
trastuzumab-modified P12-loaded nanoparticles and to levels of
128% (P < .05) with PEGylated P12-loaded nanoparticles compared
to controls (data not shown).
Figure 5. Time-dependent release of trastuzumab-modified and PEGylated nanoparticles with a Cy5-labeled ASO into BT-474 cells: (up-
per panels) PEGylated nanoparticles; (lower panels) trastuzumab-modified nanoparticles. Red: membrane staining with Alexa594 Con-
canavalin A; Blue: Cy5-labeled ASO.
Figure 6. Plk1 mRNA and protein expression in BT-474 cells after incubating with nanoparticles. (A) An RT-PCR analysis was performed
48 hours after incubating with nanoparticle formulations using primers specific for Plk1 and for GAPDH for standardization. Represen-
tative gels show Plk1 cDNA (top) and GAPDH cDNA for standardization (bottom). Percentage of Plk1 cDNA expression is given as per-
centage of GAPDH-standardized Plk1 cDNA expression in control cells (n = 8, mean ± SD). A quantitative real-time PCR analysis was
performed (B) 24 and (C) 48 hours after incubating with the nanoparticle formulations using Plk1- and GAPDH-specific primers. Graphical
summary of gene expression values of treated cells standardized to control cells are shown (n = 3–5, mean ± SD). (D–F) Western blot
analyses were performed using anti–Plk1 antibodies 24, 48, and 72 hours after incubating with the nanoparticle formulations. To control
for variability of loading, membranes were reprobed with antibodies against p38 (24 and 48 hours) or β-actin (72 hours). Representative
Western blots show Plk1 (top) and β-actin or p38 protein (bottom) for standardization. Percentage of Plk1 protein expression is given as
percentage of β-actin– or p38-standardized Plk1 levels in control cells (n = 3, mean ± SD).
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Discussion
In the present study, we developed trastuzumab-modified nano-
particles for an HER2-specific targeting of breast cancer cells with
Plk1-specific ASOs. Such biodegradable nanoparticles are well-
established systems for the delivery of drugs to cancer cells [35].
One option of drug delivery is the passive targeting due to the en-
hanced permeability and retention effect appearing in solid tumors,
because once injected into the blood stream, nanoparticles accumu-
late in the tumors [36,37]. Nevertheless, active targeting is a highly
promising strategy, because cancer cells often overexpress receptors
for various ligands compared to benign tissues [38]. These receptors
provide a promising option for the active and specific targeting of
colloidal drug carriers, such as liposomes or nanoparticles. Antibodies
or other ligands can be used to modify the surface of the nanoparti-
cles to achieve better delivery efficiency and tumor-specific target-
ing [39,40]. Typically, the antibody has to be modified to achieve
reactive groups for the linkage to the nanoparticle surface. Our
previous study showed the successful receptor-mediated uptake
of trastuzumab-modified HSA nanoparticles into different HER2-
positive breast cancer cells in culture [31]. The HER2 receptor is over-
expressed in approximately 20% to 30% of all breast cancer cases, and
there are more than 200,000 newly diagnosed breast cancer cases with-
in 1 year in the US and 55,000 in Germany [41], demonstrating the
great prominence for advancement of treatment, especially for HER2-
positive patients.
ASOs are one potential therapeutic option for the treatment of
various human cancers, and several phosphorothioate ASOs are cur-
rently being evaluated in patients [16], suggesting ASOs as valuable
agents for therapeutic approaches. Despite the promising antitumor
activity in vitro and in vivo, many ASOs have shown side effects and
toxicities in their relevant doses [16,17]. In addition, antisense ther-
apy is hindered because of poor stability in physiological fluids and
inadequate penetration into the target tumor tissue [37]. These facts
emphasize the necessity to develop smart targeted delivery systems
for ASOs [18–21]. In the present study, we developed trastuzumab-
modified and PEGylated HSA nanoparticles loaded with ASOs target-
ing Plk1 and a control ASO. Polo-like kinase 1 is a promising target
for cancer therapy because of its overexpression in diverse cancer
types and because of its correlation to poor prognosis in cancer pa-
tients [5]. Polo-like kinase 1 overexpression in normal cells leads to
transformation of cells [6], and conversely, inhibition of Plk1 induces
Figure 7. Plk2 and Plk4 expression and activation of Caspases in
BT-474 cells 72 hours after incubating with nanoparticles. (A) A
Western blot analysis was performed using anti–Plk2 antibodies.
To control for variability of loading, membranes were reprobed with
antibodies against p38. Representative Western blots show Plk2
(top) and p38 protein (bottom) for standardization. Percentage of
Plk2 protein expression is given as percentage of p38-standardized
Plk2 levels in control cells (n = 3, mean ± SD). (B) A Western blot
analysis was performed using anti–Plk4 antibodies. To control for
variability of loading, membranes were reprobed with antibodies
against p38. Representative Western blots show Plk4 (top) and
p38 protein (bottom) for standardization. Percentage of Plk4 protein
expression is given as percentage of p38-standardized Plk4 levels in
control cells (n= 3, mean ± SD). (C) Graphical summary of Caspase
3/7 activation in BT-474 cells 72 hours after incubating with nano-
particles. Percentage of luminescence is given as percentage of lu-
minescence levels in control cells (n = 3, mean ± SD).
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cell cycle arrest, apoptosis, and mitotic catastrophe, indicating a reli-
able approach to inhibit cancer cell proliferation and tumor growth.
Because of these facts, Plk1 is an attractive cancer target for many
pharmaceutical companies [42–46]. Hence, it is very important to
find delivery strategies for nucleic acid–based therapeutics, for exam-
ple, targeting Plk1 to minimize unwanted side effects [47].
In our experiments, we achieved a specific uptake of HSA nano-
particles in HER2-positive breast cancer cells, such as SK-BR-3 and
BT-474, whereas in HER2-negative MCF-7, NIH-3T3, and C2C12
cells, no significant difference between the uptake of trastuzumab-
modified and PEGylated nanoparticles was observed. The cell-specific
uptake was time-dependent in the breast cancer cells with longer in-
cubation times, leading to increased HER2-independent interactions
between nanoparticles and cells and to uptake mediated by recycled
HER2 receptors. The specific ASO-loaded nanoparticle uptake was
blocked by the preincubation with the free antibody trastuzumab
as shown before for the unloaded nanoparticles [31]. Here, after 30
and 60 minutes of incubation, uptake was comparable to PEGylated
nanoparticles, and the increase observed after 3 to 24 hours could be
due to recycled HER2 receptors or could be mediated by HER2-
independent uptake. Next, we analyzed whether this receptor-
mediated uptake is followed by a release of the ASO into the cells.
We observed strong Cy5 fluorescence after 60 minutes of incubating
with trastuzumab-modified nanoparticles and almost no fluorescence
for PEGylated nanoparticles. In addition, an HER2-independent in-
crease in Cy5 fluorescence was observed over a period of 1 to 24 hours
parallel to the HER2-independent uptake of the nanoparticles. These
data indicate that the ASOs can be released within the cell.
In addition, we analyzed whether the HSA nanoparticles show up-
take in HER2-negative murine cells. In NIH-3T3 and C2C12 cells,
no enrichment of the nanoparticles, even no HER2-independent,
time-dependent uptake was detectable. We observed an uptake of
only approximately 20% in NIH-3T3 and 40% in C2C12 cells after
24 hours of incubation. Therefore, we can conclude that this system
is suitable for in vivo studies in nude mice.
However, the most interesting aspect is the question whether the
ASOs are intact and are able to exert biologic activity against their
target gene after being released into the cytoplasm of the cancer cells.
To address this question, we performed RT-PCR, quantitative real-
time PCR, and Western blot analyses against Plk1 after incubating
the cells with the different nanoparticle formulations. We made the
observation that Plk1 mRNA and protein were statistically signifi-
cantly reduced after treatment of HER2-positive BT-474 cells with
trastuzumab-modified P12-loaded HSA nanoparticles compared to
control cells. This reduction of Plk1 expression was time-dependent
over a period of 24 to 48 hours for Plk1 mRNA and over a period of
24 to 72 hours for Plk1 protein. According to earlier studies [30], we
achieved a concentration of ASOs in the cells, which corresponds to
approximately 100 nM for a normal transfection, which is in concor-
dance with our studies using pure phosphorothioate ASOs targeting
Plk1 [10,29]. The extent of Plk1 mRNA reduction (to levels of 77%
in RT-PCR analyses and to 52% in quantitative real-time PCR anal-
yses compared to controls) and protein reduction (to levels of 38%
compared to controls) was comparable with our latest observations
after transfection of ASOs using the oligofectamine protocol [29],
so we can assume that the ASOs are released in an intact form that
can interfere with Plk1 mRNA. We did not see a reduction of Plk1
protein earlier than 72 hours after incubating with the nanoparticles,
confirming the data about the release of ASOs from nanoparticles
24 hours after incubation [30] and in accordance to the half-life time
of the Plk1 protein of approximately 9 hours. Thus, a significant re-
duction of Plk1 protein can be seen, for example, 48 hours after
transfection with pure ASOs or siRNA targeting Plk1 [9,10], but
not earlier than 72 hours after incubating with nanoparticles.
To substantiate the specificity of the Plk1 reduction, we analyzed
the effect of nanoparticles loaded with Plk1-specific ASO P12 and
with HSV ASO on the expression of two other family members of
the Plk family, Plk2 and Plk4. Seventy-two hours after incubating
with the different nanoparticles, the Plk2 and Plk4 protein expressions
did not change significantly comparing P12-loaded trastuzumab-
modified nanoparticles with HSV and untreated control cells. These
observations confirm the specificity of the Plk1 reduction by Plk1-
specific ASOs.
As a consequence of the reduction of Plk1 expression 72 hours
after incubating with the P12-loaded trastuzumab-modified nanopar-
ticles, we observed an activation of Caspase 3/7. This observation of
elevated apoptosis is in concordance with our earlier studies about
Plk1 inhibition using ASOs or siRNA [9,10,29,34]. It can be con-
cluded that the P12-loaded trastuzumab-modified nanoparticles
moderately activated the apoptotic pathway, resulting in an activation
of the Caspases 3/7.
Taken together, the ASO-loaded nanoparticles have several advan-
tages: simple and fast preparation, storage stability, efficient specific
trastuzumab-mediated uptake in HER2-positive breast cancer cells,
and minimal HER2-independent uptake in HER2-negative cells.
Compared to the efforts from various other groups for the develop-
ment of specific targeting strategies to deliver ASOs or other nucleic
acid–based agents into tumor cells [37,48–50], we developed a very
simple, safe, and cheap nanoparticle system based on HSA, which
has already achieved FDA approval as paclitaxel formulation [24,25].
In conclusion, we could show for the first time a receptor-mediated
targeting of tumor cells followed by a significant reduction of Plk1 ex-
pression in vitro and apoptosis after treatment of breast cancer cells
with ASO-loaded trastuzumab-modified HSA nanoparticles. This pro-
vides the basis for an efficient targeted delivery of drugs into tumor
cells and the prevention of side effects induced by unwanted uptake
of drugs into benign tissues.
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